Last mentioned: 1d ago
Across the most recent 1 story covering ClearPoint Neuro, Inc. — 100% neutral sentiment, averaging 5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Commercial Drug Delivery Readiness Target
ClearPoint aims to have its commercial infrastructure and installed base ready to support partner drug launches.
Q2 2026 Earnings Release
ClearPoint Neuro announces quarterly results and highlights FDA guidance reversal and commercial restructuring.
CAL Facility Possession
ClearPoint takes possession of the ClearPoint Advanced Laboratories, enabling new in-house services revenue from Q3 onward.
Second Quarter 2026 Ends
ClearPoint Neuro's fiscal Q2 concludes with $10.9M in revenue, 18% overall growth, but a 15% decline in Biologics and Drug Delivery.
Potential Partner BLA Submissions
Following FDA's rare disease guidance reversal, biopharma partners may file Biologics License Applications later this year.
ClearPoint Neuro's Q2 biologics revenue fell 15% as clinical trial product shipments slowed, but the newly operational CAL facility and an FDA regulatory pivot on rare diseases are expected to re-ignite growth in the cell and gene therapy delivery segment.
Source: theusnews.com · albuquerqueexpress.com
This page surfaces every story mentioning ClearPoint Neuro, Inc. across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where ClearPoint Neuro, Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |